dr. creelan discusses results of anti-pd-l1 antibody in combination with gefitinib in nsclc
Published 9 years ago • 716 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
1:10
dr. gubens on prevalence of egfr/alk/ros1 and pd-l1 expression in nsclc
-
2:03
dr. natale on the utility of pd-l1 and tmb in lung cancer
-
5:01
chemotherapy-tki combinations in metastatic egfr lung cancer
-
7:42
therapy approach for pd-l1 over 50% lung cancer
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
7:46
egfr and pd-l1 testing in locally advanced nsclc
-
1:29
dr. garissino on combinations with immune checkpoint inhibitors in nsclc
-
1:04
dr. fidler on relay trial results in egfr nsclc
-
4:46
tatton: phase 1b trial of combination therapies with azd9291 in egfr-mutant lung cancer
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
4:48
gefitinib approved for nsclc, atezolizumab shrinks bladder tumors, and more
-
2:36
atezolizumab with erlotinib in combination treatment for egfr mutant nsclc
-
2:01
dr. welsh on new understanding of regulating pd-l1 expression
-
3:35
novel egfr inhibitor combinations for nsclc
-
1:15
peter emtage on the combination of medi4736 and tremelimumab for nsclc
-
1:42
dr. desai on immunotherapy in patients with nsclc and low pd-l1 expression